This assay specifically identifies HPV genotypes 16 and 18 while concurrently detecting the other high risk genotypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) at clinically relevant infection levels.
Currently this assay is only validated for diagnoses not screening purposes. For asymptomatic screening, please refer to: Cervical Screening Test - Clinician Collect.
| Test of Cure |
It is recommended that patients who have received treatment for a high-grade abnormality should complete Test of Cure surveillance to confirm their treatment has been successful. Test of Cure surveillance is a co-test (HPV PCR and Liquid Based Cytology) performed twelve months after treatment and annually thereafter, until the patient receives a negative co-test in two consecutive occasions. They should then return to five-yearly screening.
This assay is indicated when high grade dysplasia has been proven histologically and cytologically.
|
| Co-Testing |
Co-testing involves the pathology laboratory performing both the HPV PCR test and Liquid Based Cytology (LBC) concurrently on the same specimen. This means the LBC test is performed irrespective of the HPV test result, without requiring an additional request.
This assay is used for testing when patients present with symptoms such as post-coital bleeding.
|
This is only indicated on testing that is for cervico-vaginal specimens.
Samples for HPV PCR which are not Female Genitalia, please refer to Human Papilloma Virus PCR.
